Potel G, Touzé M D, Meignier M, Reynaud A, Baron D
Laboratoire d'Antibiologie Expérimentale et Clinique, UER de Médecine, Nantes.
Pathol Biol (Paris). 1988 May;36(5):531-5.
Teicoplanin was evaluated in 25 severe infections caused by Gram-positive bacteria alone [13], in combination [9], alone then in combination [3], in an open study. Of 22 infections that could be evaluated, there were 18 cures and improvements (81.8%), 2 recurrence and 2 failures. Serum concentrations are unpredictable and steady after 5 days i.v. teicoplanin. Trough and peak concentrations are respectively less than 5 mg/l and less than 20 mg/l in 13 infections and higher in 9, unrelated with success or failure. A trough concentration greater than CMI and kind of infection seem deciding. The choice of the antibiotic combined with teicoplanin warrant more data.
在一项开放性研究中，对仅由革兰氏阳性菌引起的25例严重感染[13]、联合使用时的感染[9]、先单独使用后联合使用的感染[3]进行了替考拉宁评估。在22例可评估的感染中，有18例治愈和改善（81.8%），2例复发和2例失败。静脉注射替考拉宁5天后血清浓度不可预测且趋于稳定。在13例感染中，谷浓度和峰浓度分别低于5mg/L和低于20mg/L，9例感染中则更高，这与治疗成功或失败无关。谷浓度高于最低抑菌浓度（CMI）以及感染类型似乎起决定性作用。与替考拉宁联合使用的抗生素选择需要更多数据。
